Medicare outsources lab-test pricing to a single private data broker—with no transparency rules.

What it does

This bill amends Medicare's payment system for clinical diagnostic laboratory tests by requiring the government to contract with an independent nonprofit organization to collect private insurance claims data and use that data to set more accurate Medicare payment rates for these tests. Starting in 2028, Medicare will use actual private payor rates from a comprehensive claims database (containing at least 50 billion claims from over 50 insurers) instead of relying solely on laboratory self-reporting, with fallback payment adjustments if no data is available.

Why we flagged it

The bill's core function is to improve the accuracy of Medicare laboratory test payment rates by mandating use of private claims data collected by an independent nonprofit. However, the operative mechanism—contracting with a single qualifying entity to control access to a proprietary database—creates a structural dependency that may benefit the intermediary organization and the insurers whose data it aggregates, not just Medicare beneficiaries.

What the text implies

• The bill designates a single 'qualifying independent claims data entity' as the exclusive source of private payor claims data for Medicare rate-setting, creating a potential monopoly over a critical input to federal payment policy without explicit governance safeguards, transparency requirements, or conflict-of-interest rules for the intermediary.
• The 'qualifying comprehensive claims database' must contain data from 'more than 50 private payors' but the bill does not require disclosure of which payors are included, their market share, or whether the database is representative of all geographic regions and demographic groups, risking skewed payment rates based on incomplete or biased data.
• The bill requires the intermediary to be 'not affiliated with any Government agency, insurance issuer, group health plan, provider of services or supplier, or other organization in the health care sector,' but does not prohibit the intermediary from being owned by or receiving funding from such entities, creating a loophole for indirect control.
• Medicare is required to 'make available to the public an explanation of the payment rate' but the bill does not mandate that the underlying claims data, methodology, or intermediary's quality assurance processes be disclosed, limiting beneficiary and provider ability to audit or challenge rates.
• The fallback payment mechanism (CPI adjustment if no contract or data is available) may insulate the intermediary from accountability—if the entity fails to deliver data, Medicare simply increases prior-year rates, removing the incentive for the intermediary to perform and creating a permanent cost to the program.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill improves Medicare payment accuracy by incorporating real market data, potentially reducing overpayments and stabilizing beneficiary access to tests. However, the mechanism creates a dependency on a single private nonprofit data intermediary whose market power and data governance are not transparently constrained, and the bill does not explicitly protect against data misuse or ensure that savings flow to beneficiaries rather than being captured by the intermediary or insurers.

Who stands to gain

• Independent nonprofit claims data aggregator (designated intermediary)
• Private insurance companies and claims administrators (whose data becomes the basis for Medicare rat
• Laboratory testing companies (if rates are set based on data that reflects higher private payor rate

Named in the bill

Centers for Medicare & Medicaid Services (CMS), Qualifying independent claims data entity (unnamed nonprofit), Private payors and claims administrators, Clinical diagnostic laboratory providers, Advanced diagnostic laboratory tests (ADLTs), Social Security Act Section 1834A, Code of Federal Regulations Title 42 Section 414.502

Where it stands

13 cosponsors: 7 Republicans, 6 Democrats.

• Sep 10, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Sep 10, 2025 — Referred to Senate Committee on Finance · Congress.gov: “Read twice and referred to the Committee on Finance”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

31 lobbying clients named this bill on 51 disclosure filings across 3 quarters, Dec 2025 to Jun 2026. Those filings disclosed $18,491,433 in lobbying spend. A filing names 6 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 98% of bills with at least one filing.

Thom Tillis, the sponsor, reported $973,475 in PAC receipts in the 2026 cycle. $-1,000 of that came from 2 PACs tied to these lobbying clients.

• American Hospital Association — $4,470,000 on 1 filing
• American Cancer Society Cancer Action Network Inc — $3,620,000 on 2 filings
• Advanced Medical Technology Assn — $1,913,000 on 2 filings
• American Clinical Laboratory Assn — $1,820,000 on 2 filings
• Siemens Medical Solutions Usa, Inc — $860,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.